23 research outputs found
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
Smoking trends and health equity in Switzerland between 1992 and 2017: dependence of smoking prevalence on educational level and social determinants
BackgroundSwitzerland ranks among the top three healthcare systems in the world with regards to healthcare access, suggesting a high degree of health equity. However, Switzerland has few preventive strategies against smoking abuse. The aim of this study is to clarify whether educational level and citizenship status have an influence on the prevalence of smoking in Switzerland and whether there is health inequity related to a lack of preventive strategies.MethodsWe based our analysis on publicly available health data published in the Swiss government's Swiss health survey (1992â2017). We compared the prevalence of smoking across the years and correlated these data with levels of educational attainment, citizenship status and age.ResultsA continuous significant decline in smokers is observed in the highest education group (TERT). Over time, prevalence was reduced from 29% in 1992 to 23% in 2017 (p < 0.001). The intermediate-level educational group (SEK 2) showed smaller but also significant decline on a 0.05 sigificance level over the same period, from 31% to 29% (p = 0.003). The lowest educational group showed a nonsignificant decline from 28% to 27% (p = 0.6). The population who holds Swiss citizenship showed a decrease in smoking from 28% to 26% within the time frame (p < 0.001). People without Swiss citizenship had a much higher prevalence of smokers, at 38% in 1992 and declining to 32% in 2017 (p < 0.001). All cohorts from age 15 to age 64 have a far higher prevalence of smokers than cohorts at an older age, with the highest prevalence in the 25â34 age group.ConclusionIn Switzerland, individuals with lower levels of education and non-Swiss populations are more susceptible to health risk of smoking. This is despite the existence of a high-quality healthcare system that has nevertheless failed to negated health inequities
Reactivity studies on [Cp ` Fe(mu-I)](2): nitrido-, sulfido- and diselenide iron complexes derived from pseudohalide activation
bibtex: ISI:000400553000098 bibtex\location:'THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND',publisher:'ROYAL SOC CHEMISTRY',type:'Article',affiliation:'Walter, MD (Reprint Author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Anorgan & Analyt Chem, Hagenring 30, D-38106 Braunschweig, Germany. Maron, L (Reprint Author), Univ Toulouse, INSA UPS LPCNO, CNRS LPCNO, 135 Ave Rangueil, F-31077 Toulouse, France. Reiners, Matthias; Maekawa, Miyuki; Daniliuc, Constantin G.; Freytag, Matthias; Jones, Peter G.; Walter, Marc D., Tech Univ Carolo Wilhelmina Braunschweig, Inst Anorgan & Analyt Chem, Hagenring 30, D-38106 Braunschweig, Germany. White, Peter S., Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA. Hohenberger, Johannes; Sutter, Joerg; Meyer, Karsten, Univ Erlangen Nurnberg, Dept Chem & Pharm, Inorgan Chem, Egerlandstr 1, D-91058 Erlangen, Germany. Maron, Laurent, Univ Toulouse, INSA UPS LPCNO, CNRS LPCNO, 135 Ave Rangueil, F-31077 Toulouse, France.','author-email':'[email protected] [email protected]',da:'2018-12-05','doc-delivery-number':'ET8MH',eissn:'2041-6539','funding-acknowledgement':'Alexander von Humboldt Foundation; NSF [CHE-0615704]; Emmy Noether and Heisenberg program [WA 2513/2, WA 2513/6]; Humboldt Foundation','funding-text':'We thank the Alexander von Humboldt Foundation for a Feodor-Lynen Fellowship (M. D. W.) and Prof. Maurice Brookhart for providing financial support (through NSF Grant CHE-0615704) and laboratory facilities (M. D. W.) during the initial phase of this research program. Deutsche Forschungsgemeinschaft (DFG) is acknowledged for generous funding by the Emmy Noether and Heisenberg program (WA 2513/2 and WA 2513/6, respectively). LM is grateful to the Humboldt Foundation for a grant of experienced researcher and the Chinese Academy of Science. CalMip is also gratefully acknowledged for a generous computational grant.','journal-iso':'Chem. Sci.','keywords-plus':'FE2O2 DIAMOND CORE; STRUCTURAL-CHARACTERIZATION; DINITROGEN ACTIVATION; SULFUR CLUSTERS; SOLVENT PURIFICATION; MOLECULAR-STRUCTURES; ELECTRON-TRANSFER; 2FE-2S CLUSTERS; DOUBLE-BOND; FE-IVN','number-of-cited-references':'106',oa:'DOAJ Gold','orcid-numbers':'Meyer, Karsten/0000-0002-7844-2998 Daniliuc, Constantin G./0000-0002-6709-3673','research-areas':'Chemistry','researcherid-numbers':'Meyer, Karsten/G-2570-2012 Walter, Marc/E-4479-2012','times-cited':'4','unique-id':'ISI:000400553000098','usage-count-last-180-days':'4','usage-count-since-2013':'20','web-of-science-categories':'Chemistry, Multidisciplinary'\The iron half-sandwich [Cp'Fe(mu-I)](2) (Cp' = 1,2,4-(Me3C)(3)C5H2, 1) reacts with the pseudohalides NCO-, SCN-, SeCN- and N-3(-) to give [Cp'Fe(mu-NCO)](2) (2), [Cp'Fe(mu-S)](2) (3), [Cp'Fe(mu-Se-2)](2) (4) and [Cp'Fe(mu-N)](2) (5), respectively. Various spectroscopic techniques including X-ray diffraction, solid-state magnetic susceptibility studies and Fe-57 Mossbauer spectroscopy were employed in the characterization of these species. Mossbauer spectroscopy shows a decreasing isomer shift with increasing formal oxidation state, ranging from Fe(II) to Fe(IV), in complexes 1 to 5. The sulfido-bridged dimer 3 exhibits strong antiferromagnetic coupling between the Fe(III) centers. This leads to temperature-independent paramagnetism (TIP) at low temperature, from which the energy gap between the ground and the excited state can be estimated to be 2J = ca. 700 cm(-1). The iron(IV) nitrido complex [Cp'Fe(mu-N)](2) (5) shows no reactivity towards H-2 (10 atm), but undergoes clean reactions with CO (5 bar) and XylNC (Xyl = 2,6-Me2C6H3) to form the diamagnetic isocyanate and carbodiimide complexes [Cp'Fe(CO)(2)(NCO)] (7) and [Cp'Fe(CNXyl)(2)(NCNXyl)] (8), respectively. All compounds were fully characterized, and density functional theory (DFT) computations provide useful insights into their formation and the electronic structures of complexes 3 and 5
Synthesis and Characterization of Divalent Manganese, Iron, and Cobalt Complexes in Tripodal Phenolate/N-Heterocyclic Carbene Ligand Environments
Two
novel tripodal ligands, (BIMPN<sup>Mes,Ad,Me</sup>)<sup>â</sup> and (MIMPN<sup>Mes,Ad,Me</sup>)<sup>2â</sup>, combining two
types of donor atoms, namely, NHC and phenolate donors, were synthesized
to complete the series of N-anchored ligands, ranging from chelating
species with trisÂ(carbene) to trisÂ(phenolate) chelating
arms. The complete ligand series offers a convenient way of tuning
the electronic and steric environment around the metal center, thus,
allowing for control of the complexâs reactivity. This series
of divalent complexes of Mn, Fe, and Co was synthesized and characterized
by <sup>1</sup>H NMR, IR, and UV/vis spectroscopy as well as by single-crystal
X-ray diffraction studies. Variable-temperature SQUID magnetization
measurements in the range from 2 to 300 K confirmed <i>high-spin</i> ground states for all divalent complexes and revealed a trend of
increasing zero-field splitting |<i>D</i>| from MnÂ(II),
to FeÂ(II), to CoÂ(II) complexes. Zero-field <sup>57</sup>Fe MoÌssbauer
spectroscopy of the FeÂ(II) complexes <b>3</b>, <b>4</b>, <b>8</b>, and <b>11</b> shows isomer shifts ÎŽ
that increase gradually as carbenes are substituted for phenolates
in the series of ligands. From the single-crystal structure determinations
of the complexes, the different steric demand of the ligands is evident.
Particularly, the molecular structure of <b>1</b>îžin
which a pyridine molecule is situated next to the MnâCl bondîžand
those of azide complexes <b>2</b>, <b>4</b>, and <b>6</b> demonstrate the flexibility of these mixed-ligand derivatives,
which, in contrast to the corresponding symmetrical TIMEN<sup>R</sup> ligands, allow for side access of, e.g., organic substrates, to
the reactive metal center
Smoking trends and health equity in Switzerland between 1992 and 2017: dependence of smoking prevalence on educational level and social determinants
Background: Switzerland ranks among the top three healthcare systems in the world with regards to healthcare access, suggesting a high degree of health equity. However, Switzerland has few preventive strategies against smoking abuse. The aim of this study is to clarify whether educational level and citizenship status have an influence on the prevalence of smoking in Switzerland and whether there is health inequity related to a lack of preventive strategies.
Methods: We based our analysis on publicly available health data published in the Swiss government's Swiss health survey (1992â2017). We compared the prevalence of smoking across the years and correlated these data with levels of educational attainment, citizenship status and age.
Results: A continuous significant decline in smokers is observed in the highest education group (TERT). Over time, prevalence was reduced from 29% in 1992 to 23% in 2017 (p < 0.001). The intermediate-level educational group (SEK 2) showed smaller but also significant decline on a 0.05 sigificance level over the same period, from 31% to 29% (p = 0.003). The lowest educational group showed a nonsignificant decline from 28% to 27% (p = 0.6). The population who holds Swiss citizenship showed a decrease in smoking from 28% to 26% within the time frame (p < 0.001). People without Swiss citizenship had a much higher prevalence of smokers, at 38% in 1992 and declining to 32% in 2017 (p < 0.001). All cohorts from age 15 to age 64 have a far higher prevalence of smokers than cohorts at an older age, with the highest prevalence in the 25â34 age group.
Conclusion: In Switzerland, individuals with lower levels of education and non-Swiss populations are more susceptible to health risk of smoking. This is despite the existence of a high-quality healthcare system that has nevertheless failed to negated health inequities.ISSN:1664-064
Characterization of an IronâRuthenium Interaction in a Ferrocene Diamide Complex
Reaction
of [fcÂ(NH<sub>2</sub>)<sub>2</sub>]ÂRuCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (fc = 1,1âČ-ferrocenylene) with 2 equiv
of KO<sup>t</sup>Bu led to the formation of a diamido ruthenium complex,
[fcÂ(NH)<sub>2</sub>]ÂRuÂ(PPh<sub>3</sub>)<sub>2</sub>, whose solid-state
molecular structure revealed a short FeâRu distance. A metal-to-metal
charge transfer band was observed in the electronic absorption spectrum
of [fcÂ(NH)<sub>2</sub>]ÂRuÂ(PPh<sub>3</sub>)<sub>2</sub>. The FeâRu
interaction was characterized by resonance Raman spectroscopy for
the first time and also by <sup>1</sup>H NMR, UVâvis, NIR,
MoÌssbauer spectroscopy, and X-ray crystallography. Density
functional theory (DFT) calculations including natural bond order
analysis, Baderâs atom in molecules method, and time-dependent
DFT (TDDFT) provided further support that the ironâruthenium
bond is a weak donorâacceptor interaction with iron acting
as the Lewis base
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience
Contains fulltext :
125703.pdf (publisher's version ) (Closed access)BACKGROUND: Preoperative imatinib therapy of locally advanced GIST may facilitate resection and decrease morbidity of the procedure. METHODS: We have pooled databases from 10 EORTC STBSG sarcoma centers and analyzed disease-free survival (DFS) and disease-specific survival (DSS) in 161 patients with locally advanced, nonmetastatic GISTs who received neoadjuvant imatinib. OS was calculated from start of imatinib therapy for locally advanced disease until death or last follow-up (FU) after resection of the GIST. DFS was calculated from date of resection to date of disease recurrence or last FU. Median FU time was 46 months. RESULTS: The primary tumor was located in the stomach (55 %), followed by rectum (20 %), duodenum (10 %), ileum/jejunum/other (11 %), and esophagus (3 %). The tumor resection after preoperative imatinib (median time on therapy, 40 weeks) was R0 in 83 %. Only two patients have demonstrated disease progression during neoadjuvant therapy. Five-year DSS/DFS rates were 95/65 %, respectively, median OS was 104 months, and median DFS was not reached. There were 56 % of patients who continued imatinib after resection. Thirty-seven GIST recurrences were diagnosed (only 5 local relapses). The most common mutations affected exon 11 KIT (65 %). Poorer DFS was related to primary tumor location in small bowel and lack of postoperative therapy with imatinib. CONCLUSIONS: Our analysis comprising the largest group of GIST patients treated with neoadjuvant imatinib in routine practice indicates excellent long-term results of combined therapy in locally advanced GISTs
Characterization of an IronâRuthenium Interaction in a Ferrocene Diamide Complex
Reaction
of [fcÂ(NH<sub>2</sub>)<sub>2</sub>]ÂRuCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (fc = 1,1âČ-ferrocenylene) with 2 equiv
of KO<sup>t</sup>Bu led to the formation of a diamido ruthenium complex,
[fcÂ(NH)<sub>2</sub>]ÂRuÂ(PPh<sub>3</sub>)<sub>2</sub>, whose solid-state
molecular structure revealed a short FeâRu distance. A metal-to-metal
charge transfer band was observed in the electronic absorption spectrum
of [fcÂ(NH)<sub>2</sub>]ÂRuÂ(PPh<sub>3</sub>)<sub>2</sub>. The FeâRu
interaction was characterized by resonance Raman spectroscopy for
the first time and also by <sup>1</sup>H NMR, UVâvis, NIR,
MoÌssbauer spectroscopy, and X-ray crystallography. Density
functional theory (DFT) calculations including natural bond order
analysis, Baderâs atom in molecules method, and time-dependent
DFT (TDDFT) provided further support that the ironâruthenium
bond is a weak donorâacceptor interaction with iron acting
as the Lewis base
Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa)
Objective We investigated the health-related quality of life (HRQoL) of patients with gastrointestinal stromal tumours (GIST). Methods In the multicentre PROSa study, the HRQoL of adult GIST patients was assessed between 2017 and 2019 using the European Organisation for Research and Treatment of Cancer HRQoL questionnaire (EORTC QLQ-C30). We performed group comparisons and multivariate linear regressions. Results Among 130 patients from 13 centres, the mean global HRQoL was 63.3 out of 100 points. Higher sores indicate better HRQoL. The highest restrictions were in emotional, social, role functioning, insomnia, fatigue, and pain. In multivariate linear regression, we found no significant differences between patients receiving tyrosine kinase inhibitor (TKI) treatment and those without TKI treatment as well as between patients treated with curative or with palliative intent. Patients who received multiple lines of TKI treatment had the most restrictions, notably in physical (unstandardized regression coefficient [B] = -15.7), role (B = -25.7), social (B = -18.4), and cognitive functioning (B = -19.7); fatigue (B = 15.93); general health (B = -14.23); and EORTC-sum score (B = -13.82) compared to all other patients. Conclusion The highest HRQoL restrictions were in GIST patients receiving multiple lines of TKI therapy. Underlying causes need further investigation
Gastrointestinale Stromatumoren (GIST)
Gastrointestinale Stromatumoren sind mesenchymalen Ursprungs und gehören zu den seltenen malignen Tumoren. MĂ€nner und Frauen sind etwas gleich hĂ€ufig betroffen, das mediane Erkrankungsalter liegt bei 65-70 Jahren. Die hĂ€ufigsten PrimĂ€rlokalisationen liegen im Bereich des Magens und des DĂŒnndarms. Beim resektablen GIST ist die Behandlung multimodal. Bei Tumoren mit einem hohen Rezidivrisiko, das nach GröĂe des Tumors und der Mitoserate bestimmt wird, ist eine adjuvante Therapie mit Imatinib indiziert. Bei metastasierter Erkrankung ist eine medikamentöse Tumortherapie Mittel der Wahl. HierfĂŒr stehen bei Imatinib-sensitiven Tumoren in der Erstlinientherapie Imatinib, in der Zweitlinientherapie Sunitinib und in der Drittlinientherapie Regorafenib als zugelassene Substanzen zur VerfĂŒgung. Die Bestimmung des KIT- bzw. PDGFRA-Mutationsstatus ist bei GIST, bei denen eine medikamentöse Therapie indiziert ist obligater Bestandteil der Initialdiagnostik. Bei ca. 80-85% aller GIST findet sich eine Mutation des KIT-Gens, bei ca. 10-15% eine Mutation des PDGF-Rezeptors alpha (PDGFRA), beide gelten als Imatinib-sensitiv. Tumoren mit einem c-KIT/PDGFR-A Wildtyp- Status oder PDGFRA D842V Mutationen gelten als Imatinib-resistent